The table below shows Intellia Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$15.05M
$13.78M
$14.24M
$16.63M
$9.11M
$6.96M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$80.74M
$94.75M
$97.03M
$108.43M
$123.38M
$114.21M
NTLA annual revenue (10-K history)
Intellia Therapeutics, Inc. reported annual revenue of $67.67M for fiscal year 2025. That is up 16.9% from $57.88M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $16.48M (FY 2016) to $67.67M. Figures come from the company's audited annual reports as filed with the SEC.
